Investors Purchase Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of some unusual options trading on Tuesday. Stock traders purchased 111,780 call options on the company. This represents an increase of 661% compared to the average volume of 14,694 call options.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $3.10 during midday trading on Tuesday, hitting $91.17. 13,500,971 shares of the stock traded hands, compared to its average volume of 11,105,550. The firm has a market capitalization of $135.15 billion, a P/E ratio of 48.67, a PEG ratio of 1.56 and a beta of 0.67. Boston Scientific has a one year low of $85.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a 50-day moving average of $96.65 and a two-hundred day moving average of $100.16.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the previous year, the business posted $0.63 earnings per share. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. Cowen restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, January 9th. Oppenheimer lowered their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Truist Financial reduced their price objective on Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $123.89.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 93,095 shares of company stock valued at $9,305,450. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BSX. GAMMA Investing LLC raised its stake in Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after buying an additional 3,932 shares during the last quarter. State Street Corp increased its holdings in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Synergy Asset Management LLC raised its position in shares of Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after purchasing an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its stake in Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after purchasing an additional 14,700 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG grew its position in Boston Scientific by 75.3% during the 2nd quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock worth $17,685,000 after purchasing an additional 70,753 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.